Premium
Elucidation of the Interactions of an Anticancer Ruthenium Complex in Clinical Trials with Biomolecules Utilizing Capillary Electrophoresis Hyphenated to Inductively Coupled Plasma‐Mass Spectrometry. Short Communication
Author(s) -
Groessl Michael,
Hartinger Christian G.,
PołećPawlak Kasia,
Jarosz Maciej,
Dyson Paul J.,
Keppler Bernhard K.
Publication year - 2008
Publication title -
chemistry and biodiversity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 70
eISSN - 1612-1880
pISSN - 1612-1872
DOI - 10.1002/cbdv.200890148
Subject(s) - chemistry , capillary electrophoresis , biomolecule , mass spectrometry , ruthenium , inductively coupled plasma mass spectrometry , chromatography , organic chemistry , biochemistry , catalysis
The application of capillary electrophoresis (CE) combined with highly sensitive inductively‐coupled‐plasma mass spectrometric (ICP‐MS) detection allows the interactions of metal complexes with biomolecules to be characterized. This technique has been used to provide new insights into the mode of action of the ruthenium‐based anticancer drug candidate indazolium [ trans ‐tetrachlorobis(1 H ‐indazole)ruthenate(III)] (KP1019). While the compound binds rapidly and efficiently to serum proteins, especially albumin, its reactivity towards the model DNA compound 2′‐deoxyguanosine 5′‐monophosphate (5′‐dGMP) is moderate.